Highly efficacious human papillomavirus- virus like particle (HPV-VLP) vaccine induces long-lived alterations in the composition of HPV-specific B cell subsets
Presentation Time: 03:15 PM - 04:30 PM
Poster Board Number: B646
Abstract ID: 5434
Presenting Author:
Rylee J Beam , Post-Baccalaureate IRTA Fellow at NIAID, NIH
Abstract:
In an era of potentially recurring pandemics, understanding the mechanism of action of highly effective vaccines will facilitate the development of novel vaccines. Therefore, we examined the composition of B cell subsets arising from the highly effective HPV virus-like particle (VLP) vaccine, characterizing the HPV-VLP-specific (VLP+) B cell subsets in healthy human subjects with high (sero+) or low (sero-) VLP-specific serum antibodies. It was assumed that the young age sero+ group was vaccinated. We developed fluorescent HPV-VLP probes to identify VLP+ B cells. We analyzed peripheral blood mononuclear cells from 10 sero- and 4 sero+ subjects by a flow cytometric scheme that distinguishes 10 unique B cell subsets and determined the isotypes expressed on these subsets. Total VLP+ memory B cells (MBCs) were ~2-fold higher (50% of VLP+ cells) in sero+ versus sero- subjects. CD27+CD45RBMEM+CD73+ MBCs that express highly mutated BCRs were expanded 4-fold to 10% in the sero+ group. Switched VLP+ cells in sero+ subjects were 4-fold higher (29%). 39% of VLP+ cells from sero- donors were naïve anergic cells (CD73+ IgMlowIgD+) and were ~3-fold higher than the sero+ group. Thus, HPV-VLP vaccine immunization resulted in dramatic changes in VLP+ B cell subsets. These alterations may play a role in long-lasting humoral immunity induced by the HPV-VLP vaccine. Studies to understand their function should contribute to the future design of effective vaccines.
Highly efficacious human papillomavirus- virus like particle (HPV-VLP) vaccine induces long-lived alterations in the composition of HPV-specific B cell subsets
Category
Poster and Podium (Block Symposium)